Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics.

The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience. Sales from this segment rose 12% in the first quarter of 2026, lifting its contribution to 54% of total revenues from 49.7% in the first quarter of 2025. This shift signals improving revenue durability and supports a more favorable long-term growth outlook.

Within this mix, Reblozyl, Breyanzi, Opdualag, Qvantig and Cobenfy propelled growth in the first quarter.

Opdivo Qvantig (nivolumab and hyaluronidase-nvhy- subcutaneous formulation) has witnessed strong uptake across all approved tumor types in the United States.

Other key drugs are contributing to revenue growth, though at varying stages of maturity.

Opdualag sales remain robust, particularly in the United States, where it continues to serve as a standard of care in first-line melanoma.

Reblozyl recorded strong sales growth, driven by continued adoption in both first-line and second-line treatment settings for patients with myelodysplastic syndrome (MDS)-associated anemia.

Breyanzi continues to deliver solid growth, driven by ongoing uptake across its approved large B-cell lymphoma indications in both the United States and international markets. The strong performance highlights sustained demand for the therapy and supports expectations for continued commercial expansion.

Camzyos continues to gain traction in the cardiovascular market, supported by growing demand and increased adoption among eligible patients.

In immunology, Sotyktu remains an important growth driver. The recent approval in psoriatic arthritis expands its commercial opportunity and strengthens BMY's presence in rheumatology. Additional upside could come from ongoing phase III programs in systemic lupus erythematosus and Sjögren's disease, which may further broaden the drug's addressable market, if successful.

Newer therapies like Cobenfy also add optionality to the long-term story, with early launch traction and potential label expansions positioning it as a future growth lever.

The transition is not without challenges. The legacy portfolio — including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane — still represents 46% of revenues and continues to face significant erosion due to loss of exclusivity for four drugs (Revlimid, Pomalyst, Sprycel and Abraxane).

Story Continues

BMY's Competition in Oncology Space

Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space.

The company competes with big pharma giants like Merck MRK and Pfizer PFE in this space.

The immuno-oncology space is dominated by pharma giant MRK's blockbuster drug Keytruda (pembrolizumab).

Keytruda is approved for several types of cancer and alone accounts for around 55% of MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.

Pfizer is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immune-oncology biologics that treat a wide range of cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer.

Pfizer's position in oncology was strengthened with the addition of Seagen.

The company inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China.

BMY's Price Performance, Valuation & Estimates

Shares of Bristol Myers have gained 5.5% year to date against the industry's decline of 3.9%.Zacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, shares currently trade at 9.17x forward earnings, higher than its mean of 8.59x but lower than the large-cap pharma industry's 17.67x.Zacks Investment Research

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 EPS has moved north to $6.32 from $6.29 in the past 60 days, while that for 2027 has moved south to $6.05 from $6.09 in the same time frame.Zacks Investment Research

Image Source: Zacks Investment Research

BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approval for Givlaari (acute hepatic porphyria), Oxlumo (primary hyperoxaluria type 1) and Amvuttra (polyneuropathy of hATTR amyloidosis).

In 2025, Alnylam received approval in the United States and the EU for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. Following the label expansion, Amvuttra became the first and only RNAi therapeutic approved in the United States and the EU for both ATTR-CM and hATTR-PN in adults, marking a significant milestone.

Currently, Amvuttra (vutrisiran), its newest drug, is Alnylam's primary top-line driver. The drug generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. The figure accounted for 76% of Alnylam's total revenues generated in the quarter. The drug's solid uptake has been driven by increased patient demand, mainly in ATTR-CM patients in the United States, as well as several patients switching from Onpattro.

This label expansion is expected to continue boosting Amvuttra sales in the quarters ahead. Alnylam also expects approvals for Amvuttra for the ATTR-CM indication in other geographies this year. This will expand the eligible patient population for the drug, driving substantial growth for the company in the future.

ALNY's Competition in the Market for ATTR Treatments

Alnylam's Amvuttra faces notable competition in the ATTR-CM market from Pfizer's PFE Vyndaqel/Vyndamax (tafamidis) and BridgeBio's BBIO Attruby (acoramidis), both of which are already approved for this indication. While Amvuttra is positioned with a differentiated clinical profile, Pfizer's and BridgeBio's therapies carry the advantage of oral administration and comparatively lower list prices in the United States. These factors could influence prescribing decisions and pose challenges to Alnylam's competitive positioning in this space.

Vyndaqel is one of the key in-line products that has driven improvement in Pfizer's revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer's Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.

Story Continues

Approved in late 2024, Attruby is BridgeBio's only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.

ALNY's Stock Price, Valuation and Estimates

Shares of Alnylam have plunged 27.3% so far this year compared with the industry's 4% decline. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.

ALNY Stock Price MovementZacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company's shares currently trade at 9.33 trailing 12-month sales per share, higher than 2.25 for the industry. However, the stock is also trading much below its five-year mean of 18.40.

ALNY Stock ValuationZacks Investment Research

Image Source: Zacks Investment Research

Estimates for Alnylam's 2026 earnings have improved from $9.13 to $9.22 per share in the past 60 days, while the estimates for 2027 earnings have deteriorated from $14.59 to $13.68 over the same timeframe.

ALNY Estimate MovementZacks Investment Research

Image Source: Zacks Investment Research

Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with massive scale.

These two companies operate at opposite ends of the size spectrum, with one focusing on specialized precision medicine while the other manages a vast portfolio of vaccines and therapies. This comparison explores their recent financial health and risk profiles.

The case for Lexicon Pharmaceuticals

Lexicon Pharmaceuticals operates as a contender among biotech stocks by utilizing gene science to develop treatments for chronic conditions. The company primarily focuses on its commercial product, INPEFA, while licensing its programs to partners like Viatris for international markets. Specific customer concentration data was not disclosed in recent filings.

In FY 2025, revenue reached nearly $49.8 million, representing approximately 60% growth over the previous year. Despite this improvement, the company reported a net loss of $50.3 million for the period.

As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.6x. This ratio compares total debt to shareholder equity, indicating the extent to which a firm relies on borrowed money.

The case for Pfizer

Pfizer is a global biopharmaceutical leader that discovers, manufactures, and distributes medicines and vaccines across approximately 200 countries. With a workforce of nearly 75,000 employees, the company maintains a dominant presence in both developed and emerging markets. Its scale allows it to manage a massive product pipeline simultaneously, though specific major customers are not disclosed in its filings.

During FY 2025, revenue reached approximately $62.6 billion, representing a slight decrease of nearly 1.6% from the prior year. The company reported net income of roughly $7.8 billion. This level of profitability resulted in a net margin of close to 12.4%.

Based on the December 2025 balance sheet, the debt-to-equity ratio was approximately 0.8x. Free cash flow for the fiscal year was approximately $9.1 billion, providing substantial capital for dividends and research.

Risk profile comparison

Lexicon Pharmaceuticals faces significant regulatory risks, particularly regarding the approval process for candidates such as ZYNQUISTA for type 1 diabetes. The company also carries an accumulated deficit of nearly $2.0 billion, which may necessitate additional capital raises on unfavorable terms. Furthermore, a single entity, Artal Group, holds roughly 35% of the shares, limiting the influence of smaller retail shareholders.

Story Continues

Pfizer faces significant revenue concentration, with 12 products accounting for roughly 65% of its total 2025 revenue. The company faces a period of patent expirations between 2026 and 2030, which could lead to significant competition from generic drug makers. Additionally, government pricing regulations and competition from large peers such as Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) could affect long-term profitability.

Valuation comparison

While Lexicon Pharmaceuticals lacks a Forward P/E due to its net losses, Pfizer appears much more affordable based on its P/S ratio.

Metric Lexicon Pharmaceuticals Pfizer Sector Benchmark Forward P/E n/a 8.7x 24.9x P/S ratio 16.8x 2.3x

Sector benchmark uses the SPDR XLV sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

Finding a low-priced, development-stage biotech stock that explodes into a long-term 10-bagger on the success of a treatment that eventually reaches market is a dream for investors. Unfortunately, it usually stays that way: a dream that doesn’t become reality. Development-stage pharma companies often fail to get a blockbuster drug to market.

Lexicon Pharmaceuticals is not exactly development stage. It has one product on the market, INPEFA, for a once-a-day tablet for treating heart failure, but it generated just $1.1 million in sales in the first quarter of 2026. Most of the interest around Lexicon is for developmental drugs for chronic pain and cardiometabolic treatments. There are some positives in the trials, but it’s always worth keeping in mind that positive trials can still fail to bring a drug to market due to late regulatory rejections or a developer’s belief that the drug won’t find much market. Lexicon’s low stock price, which has traded between $1 and $2.50 since July 2025, indicates the speculative nature of the business.

Pfizer isn’t a hot growth stock, but it’s also one of the giants of the pharmaceutical industry. The company had a post-COVID letdown of sorts, as pandemic-related demand ebbed, but the business has been flexing its might this year. In its first quarter, Pfizer beat Wall Street analysts’ expectations on sales and net income. That is partly because Pfizer has been buying growth — it recently acquired oncology specialist Seagen and posted 20% growth in that business’s products. Prifzer is also allocating significant resources to new drug development, with 20 drug development starts scheduled for 2026 and eight data readouts expected, which report on the progress of treatments in development. After falling behind in the GLP-1 weight-loss drug market, Pfizer is also making strides toward becoming a competitor, with very positive Phase II (of III) trial results for an injectable GLP-1 reported earlier this year.

With more than $6 billion in cash, a forward price-to-earnings ratio of a bargain basement 8.7, and a tasty yield of 7% based on its recent price of $26, Pfizer is the choice for 2026.

Should you buy stock in Lexicon Pharmaceuticals right now?

Before you buy stock inLexicon Pharmaceuticals, consider this:

The Motley FoolStock Advisoranalyst team just identified what they believe are the 10 best stocksfor investors to buy now… andLexicon Pharmaceuticalswasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $442,220! Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $1,230,114!

That performance is why people listen. With a track record ofbeating the S&P 500 by nearly 5x,Stock Advisoroffers a distinct advantage. Don't miss the latest top 10 list, available withStock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of June 11, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Merck, and Pfizer. The Motley Fool has a disclosure policy.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? was originally published by The Motley Fool

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Amgen AMGN is one of the several drug makers racing to develop an innovative weight-loss drug and take a share of the booming weight loss drug market. The global obesity drug market is projected to grow dramatically, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates.

Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing. This key feature differentiates it from Eli Lilly’s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound (tirzepatide) and Wegovy (semaglutide), respectively, which are weekly injections. A monthly therapy like MariTide may help reduce treatment burden for patients and improve persistence on treatment over time.

Amgen is evaluating MariTide in type II diabetes, obesity and obesity-related conditions as part of its comprehensive MARITIME phase III program. Amgen has nine global phase III studies underway with MariTide in obesity and other obesity-related conditions like obstructive sleep apnea, cardiovascular disease and heart failure. Three phase III studies of MariTide in type II diabetes will be initiated in 2026.

In clinical studies, it has shown predictable and sustained weight loss and a clinically meaningful impact on cardiometabolic parameters.

In phase II studies, MariTide resulted in up to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau in people who were obese or overweight but without type II diabetes. In patients with type II diabetes who were obese or overweight, the weight loss reduction was approximately 17% at 52 weeks.

An interesting study is a new phase III switch study that will assess patients transitioning from weekly tirzepatide or semaglutide therapy to MariTide administered once every eight weeks or once every 12 weeks. In other words, the study will evaluate switching from Zepbound and Wegovy injections given 52 times a year to a medicine that can be injected 4 or 6 times a year.

MariTide is by far Amgen's most important obesity asset. However, Amgen’s obesity pipeline also includes earlier-stage oral and injectable candidates like AMG 513 and AMG 786.

Can AMGN Take Share from LLY and NVO in the Obesity Space?

MariTide is a closely watched drug in the obesity market. However, with MariTide, Amgen is entering a market that is heavily dominated by Lilly and Novo Nordisk. LLY and NVO already have a massive first-mover advantage in the obesity space and enjoy strong brand recognition.

Story Continues

Moreover, to maintain their prowess in the lucrative obesity market, both Novo Nordisk and Lilly are developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates.

Lilly's next-generation candidate, retatrutide, has demonstrated approximately 28% weight loss in late-stage studies, significantly above MariTide's approximately 20%.

This will make it difficult for Amgen to capture rapid market share on a weight-loss efficacy basis, even with a differentiated product like MariTide. However, from another perspective, the obesity market is huge and can support multiple players, and even a modest market share could translate into billions of dollars in annual revenues. MariTide’s less frequent dosing is its biggest competitive advantage, and if successfully developed and launched, MariTide could become the preferred option for patients who value convenience and durable weight maintenance.

Competition Heating Up in the Obesity Space

While Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics and Viking Therapeutics are also developing oral GLP-1 drugs for treating obesity.

Others, such as Roche, Merck, AbbVie, and, more recently, Pfizer PFE, have strengthened their obesity pipelines through licensing deals and acquisitions involving smaller biotechs. Pfizer has strengthened its obesity presence with last year’s licensing of YP05002 from YaoPharma and the acquisition of Metsera. AbbVie entered the obesity field by licensing GUB014295 from Gubra. Roche strengthened its obesity presence through the acquisition of Carmot Therapeutics and its obesity assets, such as CT-388, as well as the exclusive collaboration with Zealand Pharma.

AMGN’s Price Performance, Valuation and Estimates

Amgen’s stock has risen 5.3% so far this year compared with an increase of 4.0% for the industry.Zacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 15.05 forward earnings, which is lower than 17.59 for the industry. The stock is also trading above its five-year mean of 13.81.Zacks Investment Research

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for earnings has declined from $22.29 per share to $22.26 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has risen from $23.43 to $23.70 per share over the same timeframe.Zacks Investment Research

Image Source: Zacks Investment Research

Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quick Read

Tuesday's 'buy the dip' rally failed again, leaving the Nasdaq down 1% and S&P 500 lower, while bond yields pulled back from key resistance levels. Nike (NKE) was cut to Sector Perform at RBC with a $50 target, while STM was upgraded to Buy at Bank of America targeting $100. Oil dropped 3% as Iran peace optimism and increased Strait of Hormuz traffic drove selling, offering pump relief during the summer driving season. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bill Holdings didn't make the cut. Grab the names FREE today.

Pre-Market Stock Futures:

Futures are trading lower after the stock market tried to take a cue from Monday's action, and things didn't work out quite as well on Tuesday. Once again, the market gapped open higher as the "Buy the dip" legions came in to ride what they thought would be another wave higher, only to once again see the gains reversed. This time, Monday's pattern repeated, but the damage was greater: two of the four major indices closed lower, with the Dow Jones Industrial Average, which was the only index to close lower on Monday, finishing the session higher at 50,871, up 0.17%. The small-cap-heavy Russell 2000 closed the day at 2,864, up 0.32%. The Nasdaq finished the day down 0.97% at 25,678, while the S&P 500 was last seen down 0.26% at 7,386.

Treasury Bonds:

Yields were down across the Treasury curve, as every time the long end gets over the 5% levels, and the 10-year trades above 4.50%, the buyers return. Part of this is a yield play, but another big factor is adding some insurance, and many see an inevitable big decline coming our way. Either way, when the dust settled on Tuesday, the 30-year-long bond closed the day at 5.01%, while the benchmark 10-year note was last seen at 4.53%. Today's report on the Consumer Price Index for May and Thursday's Producer Price Index print could shape how the bond market trades for the rest of the second quarter.

Oil and Gas:

Oil prices were down across the board on Tuesday, as hopes for an end to the war with Iran surged on positive comments from the president, plus reports indicating that traffic in the Strait of Hormuz has increased, all of which added to the selling pressure, which Americans are cheering as the busy summer driving season is underway. Brent Crude closed the day at $91.65, down 2.75%, while West Texas Intermediate was last seen at $88.51, down 3.06%. The final trade for Natural Gas was reported at $3.14, down 3.o2%.

Gold:

The precious metals had a tough day, as trading remained range-bound for both Gold and Silver. This comes as Paul Wong, Sprott's market strategist, reminded investors that rising debt and inflation will remain the wind in the sails of the precious metals complex, which, as we have noted, has traded range-bound since late February. Gold closed Tuesday's session at $4,259, down 1.61%, while the last trade for Silver was reported at $65.21, down a whopping 4.08%.

Story Continues

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bill Holdings didn't make the cut. Grab the names FREE today.

Crypto:

Cryptocurrency markets declined on Tuesday, with Bitcoin trading near $62,500 after posting a roughly 1% loss over the past 24 hours. The broader digital asset market stayed under selling pressure as investors digested ongoing ETF outflows. Mid-week trading showed disappointing momentum, with crypto largely decoupling from a global rally in risk assets, which has run into a wall over the last two days. Although geopolitical tensions appeared to ease, concerns lingered about the prolonged streak of outflows from U.S. spot Bitcoin ETFs. At 8 AM EDT, Bitcoin traded at $62,030, while Ethereum traded at $1,659.

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.

Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Wednesday, June 10, 2026.

Upgrades:

Cava Group (NYSE: CAVA) was upgraded to Buy from Neutral at UBS, which bumped the target price for the stock to $90 from $85. Entergy(NYSE: ETR) was upgraded to Outperform from In Line at Evercore ISI, which raised the target price for the utility giant to $121 from $115. GlobalFoundries (NASDAQ: GFS) was upgraded to Buy from Neutral at Arete, without a target price. Pfizer (NYSE: PFE) was upgraded to Sector Perform from Underperform at RBC Capital, with a $25 target price. STMicroelectronics (NYSE: STM) was raised to Buy from Neutral at Bank of America, which raised the target price for the shares to $100 from $83.

Downgrades:

BILL Holdings (NYSE: BILL) was cut to Hold from Buy at Truist, which dropped the target price for the stock to $35 from $45 Hess Midstream (NYSE: HESM) was cut to Underweight from Equal Weight at Morgan Stanley, which has a $38 target price. Nike (NYSE: NKE) was downgraded to Sector Perform from Outperform at RBC Capital, which cut the target price for the sports apparel and shoe giant to $50 from $70. Nuvalent (NASDAQ: NUVL) was downgraded to Hold from Buy at TD Cowen, which dropped the target price for the share to $124 from $140. Taylor Morrison(NYSE: TMHC) was downgraded to Peer Perform from Outperform at Wolfe Research, with a $72.50 target price. That is the amount Berkshire Hathaway is paying to acquire the company.

Initiations:

3M Company (NYSE: MMM) was initiated with an Underperform rating at Bernstein, with a $131 target price. HoneywellInternational (NYSE: HON) was started with a Market Perform rating at Berstein, with a $233 target price. Power Integrations (NASDAQ: POWI) was started with a Buy rating at Needham, with a $90 target price objective. SharkNinja (NYSE: SN) was initiated with an Overweight rating at Piper Sandler, with a $150 target price. Vertiv Holdings (NYSE: VRT) was started with an Outperform rating at Bernstein, and has a $416 target price for the stock.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bill Holdings didn't make the cut. Grab the names FREE today.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Amneal Pharmaceuticals baut eine Wachstumsgeschichte auf, die weniger auf einzelnen Produkten als auf Skalierung in komplexen Medikamenten basiert. Die ersten Quartalsergebnisse haben diese Einstellung bestätigt, mit Umsatzerlösen und Gewinnen, die besser als erwartet ausfielen.

Die Zusammenarbeit von Amneal mit Metsera (jetzt Teil von Pfizer) für Glukagon-Like-Peptid-1-Therapien nutzt Amneals Infrastruktur für Peptide und sterile Injektionsprodukte, um die Produktion von Pfizers GLP-1- und verwandten metabolischen Therapien zu unterstützen.

Strategisch ist dies wichtig, da es einen Schwenk hin zu höherwertigen komplexen Injektionsprodukten und Peptidtherapeutika unterstreicht. Es hilft auch dabei, Amneal weniger als eine traditionelle Generika-Geschichte darzustellen und mehr als eine Plattform, die die Herstellung von Fertigung in schnel wachsenden Kategorien skalieren kann.

Die Partnerschaft bietet Einnahmenexpositionen, die mit dem rapiden Wachstum metabolischer Therapien zusammenhängen, ohne dass Amneal die klinischen Entwicklungskosten und das Risiko von Fehlschlägen bei der Entdeckung neuer Medikamente trägt.

Das ist entscheidend in einem Markt, der von Innovatoren wie Novo Nordisk und Eli Lilly dominiert wird, wo klinische Ergebnisse, Zulassungen und Zugang zu Zahlern das Geschäft bestimmen können. Für Amneal sind die Wirtschaftlichkeiten mit der Ausführung der Fertigung und Kapazität verbunden und nicht mit den Leserichtlinien.

Amneal nutzt die Zusammenarbeit auch, um seine Fähigkeiten in Peptide und sterile Injektionsprodukte zu vertiefen. Die Gesellschaft beschreibt diese Infrastruktur als 'wachsend' und die Pfizer-gelinkte Arbeit wird als Katalysator angesehen, der die Fertigungsfähigkeit stärkt und Glaubwürdigkeit in komplexer Produktion aufbaut.

Im Laufe der Zeit kann dies die Positionierung von Amneal bei anderen komplexen Injektionsmöglichkeiten verbessern. Die Logik ist einfach: Kapazitäten, die für anspruchsvolle metabolische Therapien gebaut werden, können ein breiteres Portfolio unterstützen und die Ansprechbarkeit von Amneal in höherwertigen Dosierungsformen erweitern.

Amneals Kashiv-Deal könnte Biosimilare vertiefen. Im April 2026 unterzeichnete Amneal einen endgültigen Vertrag zur Übernahme von Kashiv BioSciences für bis zu 1,10 Milliarden US-Dollar. Die Struktur umfasst 375 Millionen US-Dollar in bar und 375 Millionen US-Dollar in Aktien sowie bis zu 350 Millionen US-Dollar an Meilensteinzahlungen, die mit regulatorischen und kommerziellen Erfolgen verbunden sind.

Die Transaktion soll im zweiten Halbjahr 2026 abgeschlossen werden, unter Vorbehalt der üblichen Abschlussbedingungen. Das Ziel ist es, Amneal als vollständig integrierte globale Biosimilars-Plattform zu positionieren.

Das ist wichtig, da Biosimilare nicht nur ein Produktkategorie sind. Sie erfordern tiefes Entwicklungswissen, Fertigungstüchtigkeit und kommerzielle Koordination. Etablierte Biosimilar-Spezialisten wie Sandoz Group AG zeigen, wie Skalierung und Wiederholung zu einem Vorteil werden können, wenn die Plattform aufgebaut ist.

AMNEAL PHARMACEUTICALS, INC. Price and Consensus AMNEAL PHARMACEUTICALS, INC. Price and Consensus

AMNEAL PHARMACEUTICALS, INC. price-consensus-chart | AMNEAL PHARMACEUTICALS, INC. Quote

Die Wachstumsalgorithmen von Amneal hängen vom Tempo ab. Die Gesellschaft erwartet Affordable Medicines zu beschleunigen, mit einem Segment-Umsatzwachstum von 7% bis 8% in 2026, unterstützt durch 20 bis 30 neue Produktstarts pro Jahr, einschließlich komplexer Produkte.

Biosimilare sind Teil dieses Impulses. Eine Biosimilar-Version von Novartis' Xolair wird überprüft und die Zulassung würde Amneal auf sechs Biosimilare in den USA bringen.

Gleichzeitig unterstreichen jüngste regulatorische Fortschritte die Richtung des differenzierten Formates. Die FDA hat Amneals Romidepsin-Injektionslösung in einer bereitgestellten Vial-Formate zugelassen, was das Management als bequemer darstellt als ein Pulver, das gemischt werden muss. Das Produkt ist auch für die Competitive Generic Therapy-Zulassung qualifiziert, die 180 Tage Marktexklusivität bietet.

Die nähere Zukunft bringt einen Hinderungsgrund in Form von Specialty. Die Management erwartet, dass der Umsatzwachstum bei Specialty etwa flach bleibt, da Crexont-Wachstum den erwarteten Generika-Erosion von Rytary abmildert, das bereits ein autorisiertes Generikum gesehen hat und weitere Generika-Neueinträge erwarten lässt.

Druck kann auch von der Basisgeschäft kommen. Die U.S.-Generika bleiben intensiv konkurrierend, und Preisdruck kann Margen sogar dann drücken, wenn Volumina gesund sind.

Schließlich bleibt das Risiko der Ausführung und des Zeitpunkts bei komplexen Produkten real. Komplexe Injektionsprodukte, Biosimilare und Nischen-Spezialitäten unterliegen strengen Fertigungserfordernissen und rigoroser regulatorischer Überprüfung, und Verzögerungen oder langsamer als erwartetes Eintreten können die Zeiträume stören.

Was zu beobachten ist, während des zweiten Halbjahres 2026 für AMRX

Man sollte den Fortschritt der Kashiv-Aufnahmeschluss im zweiten Halbjahr 2026 und alle Updates verfolgen, die mit regulatorischen und kommerziellen Meilensteinen zusammenhängen, die das Gesamtkonsiderationsgeld prägen.

Außerdem achten Sie auf die Ausführung bei komplexen Injektionsprodukten, wo unterschiedliche Formate und Exklusivitätsfenster den Mix verbessern können. Die Gesellschaft dringt offensichtlich tiefer in höherwertige Injektionsprodukte ein, und das Pfizer-gelinkte metabolische Fertigungswerk setzt die Maßstäbe für operative Leistung.

Die Wachstumsaussichten von Amneal für 2026 sehen vor, dass der Umsatz zwischen 3,05 Milliarden und 3,15 Milliarden US-Dollar und das bereinigte EBITDA zwischen 740 Millionen und 770 Millionen US-Dollar liegen wird, was die Fortschritte in der Rentabilität und Cash-Generation widerspiegelt, während sie sich für höherwertige Produkte einsetzt.

AMRX's Zacks-Rang

Amneal hat derzeit einen Zacks-Rang #2 (Kaufen). Sie können den vollständigen Liste von heute Zacks #1 Rang (Starke Kauf) Aktien hier ansehen.

Möchten Sie die neuesten Empfehlungen von Zacks Investment Research? Heute können Sie 7 Best Stocks for the Next 30 Days herunterladen. Klicken Sie, um dieses kostenlose Bericht zu erhalten

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.

Most Read from Bloomberg

House Republican Says Hegseth's D-Day Remarks 'Inappropriate' LA Mayor Race Flips as Socialist Beats Reality TV Star Pratt Trump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal Trump's $100,000 H-1B Visa Application Fee Rejected by Judge Chip Stocks Rally in AI Trade Revival After Plunge: Markets Wrap

GSK will pay $124 a share in cash for Nuvalent, according to a statement Tuesday, a 40% premium over the Cambridge, Massachusetts-based company's closing share price on Monday. It marks a significant expansion of GSK's cancer portfolio, which has been slowly growing since the British drugmaker returned to the disease space in 2019, as well as the first major acquisition for Chief Executive Officer Luke Miels.

Since taking over at the start of this year, Miels has been working to revitalize GSK, which doesn't have a history of risk-taking and has long struggled to allay investors' fears about the drugs it has in development.

GSK shares fell as much as 3% in early trading in London. The stock is up by around 23% over the past 12 months.

Nuvalent designs precisely-targeted therapies for oncology patients including lung cancer. Its shares have declined by 12% this year, giving it a market value of almost $7 billion.

Two of the medicines GSK is acquiring are in late-stage trials, with the US Food and Drug Administration expected to decide on regulatory approval later this year. Both could be blockbuster medicines if approved, GSK said.

The Nuvalent deal won't impact GSK's guidance for the year, and it's expected to contribute to revenue growth from 2027, according to the statement.

The two leading drugs from Nuvalent treat non-small-cell lung cancer patients that have specific mutations. These mutations usually affect people who didn't smoke.

The fortunes of GSK and rival British drugmaker AstraZeneca Plc diverged in 2014 as Astra CEO Pascal Soriot worked to make the company a cancer drug powerhouse.

GSK meanwhile divested its oncology portfolio in an asset swap with Novartis in 2014. Miels, a protégé of Soriot, left Astra acrimoniously, with the company suing him in 2017, alleging he was in violation of his employment agreement. The two companies settled, with Miels joining GSK later that year.

Story Continues

Well-liked by investors, the pick of Australian Miels to succeed Emma Walmsley as CEO was seen as a move that could rejuvenate GSK. The drugmaker, known for its vaccines, has focused on immunology and HIV as vaccine sales have slowed.

In January, GSK agreed on a $2.2 billion deal to buy US biotech Rapt Therapeutics, which develops treatments for inflammatory and immunologic diseases. The firm secured a pulmonary hypertension drug in another transaction.

The Nuvalent purchase is expected to be completed by the third quarter, pending regulatory approvals. The transaction will be funded mainly through new and existing debt facilities plus cash and won't affect GSK's credit rating, the company said.

--With assistance from Michelle F. Davis.

(Updates with shares in fourth paragraph.)

Most Read from Bloomberg Businessweek

Chinese Diners Will Wait Five Hours for This Conveyor-Belt Sushi SpaceX IPO Forces Investors to Bet on Musk's Entangled AI Empire Men in Blazers Is Coming to Take Over the World Cup Where's the Global Economic Meltdown? What Trump Delivered for Amazon

©2026 Bloomberg L.P.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Biotech-Riese geht gegen den Markt, aber sein wahrer Wert für Investoren liegt in einer Geschichte, die sich über Jahre entfaltet und nicht nur Tage. ... (übersetzt vollständig)

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Pfizer hat ein reiches Pipeline von Medikamenten in Entwicklung, die wahrscheinlich gut verkauft werden. UPS hat sich von Amazon.com abgewandt und sich auf lukrativere Lieferungen konzentriert. Der Schwab U.S. Dividend Equity ETF bietet sowohl Dividenden als auch Wachstum an. Die drei vorgeschlagenen Aktien sind Pfizer, United Parcel Service (UPS) und der Schwab U.S. Dividend Equity ETF.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investing.com -- Pfizer Inc (NYSE:PFE) hat detaillierte Strategiepläne und klinische Daten für seine experimentelle Gewichtsabbauminjektion vorgestellt, um einen Fuß in der von Konkurrenten dominierten Adipositas-Markt zu sichern. Der New Yorker Pharmakonzern arbeitet daran, die führenden Unternehmen Eli Lilly und Company (NYSE:LLY) und Novo Nordisk A/S (NYSE:NVO) einzuholen, die durch ihre Vormachtstellung einen großen Marktanteil erworben haben.

Nach früheren klinischen Rückschlägen hat Pfizer sein metabolisches Pipeline durch den im vergangenen Jahr erfolgten 10-Milliarden-Dollar-Aufkauf von Metsera Inc. überarbeitet. Das Unternehmen nutzte die American Diabetes Association-Konferenz in New Orleans, um neue Daten zu berobenatide vorzustellen, einem langwirkenden GLP-1-Rezeptor-Agonist-Peptid, das aus dieser Transaktion stammt.

"Wir betreten eine neue Ära der inneren Medizin-Innovation", sagte Chris Boshoff, Chef-Wissenschaftsoffizier von Pfizer, in einem Interview mit Bloomberg vor der Konferenz. In den Ergebnissen des Phase-2b-VESPER-1-Studie erreichten Patienten bei der Übergabe auf die höchste wöchentliche Dosis einen Gewichtsverlust von 15,9% über acht Monate ohne Plateau.

Weitere Daten aus dem VESPER-3-Trial zur Bewertung von übergewichtigen oder adipösen Patienten ohne Diabetes zeigten, dass Individuen, die die höchste Dosis alle vier Wochen erhielten, nach 14 Monaten fast 15% ihres Körpergewichts verloren. Pfizer betonte, dass das Medikament das erste einmal-monatliche Therapeutikum in seiner Klasse werden könnte, was es gegenüber wöchentlichen Optionen wie Zepbound und Wegovy zu einem einzigartigen Vorteil in Bezug auf Komfort bringt.

"In Phase-2b-Studien lieferte berobenatide kontinuierliche, ununterbrochene Gewichtsabnahme bei allen für die Phase-3 ausgewählten Dosen, während sie ein tolerables Profil bei der Übergabe von einer wöchentlichen zu einer monatlichen Wartungsdosis beibehielt", sagte Jim List, Chef des inneren Medizinbereichs von Pfizer in einem Samstags-Presseerklärung. List fügte hinzu, dass Pfizers kommerzielles Netzwerk einen Vorteil bietet, da die Adipositas-Behandlung sich auf Primärversorger umschichtet, indem er sagte: "Wir haben Primärversorgung in unserem DNA."